Fetal Supraventricular Tachycardia: What the Adult Cardiologist Needs to Know
| Autor: | Joe F Lau, Sutopa Purkayastha, Diana S. Wolfe, Joao Fontes, Anna E. Bortnick, Michael Weinreich |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Digoxin Article Cardiologists Pregnancy Fetal hydrops Tachycardia Supraventricular medicine Humans cardiovascular diseases Intensive care medicine Flecainide Fetus business.industry Sotalol Transplacental General Medicine medicine.disease Fetal Arrhythmia Fetal Diseases Female Supraventricular tachycardia Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents medicine.drug |
| Zdroj: | Cardiol Rev |
| ISSN: | 1061-5377 |
| DOI: | 10.1097/crd.0000000000000370 |
| Popis: | Fetal supraventricular tachycardia management is challenging, with consequences for both the fetus and the mother. If left untreated, fetal hydrops may ensue, at which point delivery and treatment of the arrhythmia is preferred. However, if the fetus is not at term nor near-term, significant doses of antiarrhythmics may be needed to achieve adequate transplacental bioavailability. Although digoxin has classically been the mainstay of treatment, the use of flecainide or sotalol as monotherapy or in combination with digoxin is being studied. Interdisciplinary team management and shared decision-making between the physician and patient are key to achieving successful outcomes. Adult cardiologists, particularly inpatient consultation services or through burgeoning cardio-obstetrics programs, may, in some practice settings, be asked to evaluate or co-manage pregnant women with fetal arrhythmia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|